We are analyzing https://link.springer.com/article/10.1007/s10549-006-9492-5.

Title:
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer | Breast Cancer Research and Treatment
Description:
Background TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the impact of TOP2A amplification on the outcome of a series of patients homogeneously treated with adjuvant anthracyclines. Methods A cohort of 245 patients with early breast cancer homogeneously treated with anthracyclines in the adjuvant setting was selected. A tissue microarray containing these cancers was used to determine HER2 and TOP2A gene copy number by means of chromogenic in situ hybridization. Immunohistochemical staining of topoisomerase II alpha was also performed using a monoclonal antibody (Ki-S1). TOP2A amplification and protein expression were correlated with classical prognostic parameters, expression of immunohistochemical markers and with a gene expression profiling classification using surrogate immunohistochemical markers. Kaplan–Meier method was used to construct survival curves and results were compared with log-rank test. Results TOP2A amplification was restricted to tumours with HER2 amplification and was significantly associated with ER positivity. In the subgroup of patients with HER2 amplified tumours, TOP2A amplification predicted a better overall survival and disease free survival (P = 0.028 and 0.026, respectively). On multivariate analysis, TOP2A amplification maintained its predictive value for DFS. Conclusion TOP2A amplification is likely to be a useful marker to predict the subset of patients who will benefit from anthracyclines.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, breast, article, google, scholar, cas, pubmed, topoisomerase, amplification, predictive, iialpha, adjuvant, expression, patients, alpha, topa, gene, clin, chemotherapy, early, molecular, oncol, response, res, research, anthracyclines, treated, situ, prognostic, pathol, doxorubicin, reisfilho, markers, primary, cyclophosphamide, privacy, cookies, content, arriola, lambros, protein, cancers, chromogenic, hybridization, immunohistochemical, access, med, therapy, receptor, fluorouracil,

Topics {✒️}

month download article/chapter axillary lymph node-positive node-negative tumors 2 cm topoisomerase-ii alpha expression early breast cancer socorro maria rodriguez-pinilla reis-filho department neoadjuvant anthracycline-based chemotherapy primary anthracycline-based chemotherapy 2/neu-amplified breast cancer related subjects patients homogeneously treated topoisomerase ii alpha topoisomerase ii-alpha breast cancer treatment full article pdf direct molecular target operable breast cancer breast cancer staging reis-filho eukaryotic topoisomerase ii privacy choices/manage cookies metastatic breast cancer human breast cancer kellokumpu-lehtinen pl dna topoisomerase ii gene expression patterns breast tumor subtypes topoisomerase iialpha expression topoisomerase iialpha associate mitch dowsett & jorge invasive breast carcinoma anthracycline-based therapy topoisomerase iia amplifications article arriola malignant breast tissue di leo tissue-based detection growth fraction determination topo-isomerase iialpha cancer research molecular genetic studies european economic area pierga jy thor ad long-term follow unlocking pathology archives royal marsden hospital top2a amplification predicted top2a amplification maintained

Questions {❓}

Brenton JD, Carey LA, Ahmed AA et al (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
         description:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the impact of TOP2A amplification on the outcome of a series of patients homogeneously treated with adjuvant anthracyclines. A cohort of 245 patients with early breast cancer homogeneously treated with anthracyclines in the adjuvant setting was selected. A tissue microarray containing these cancers was used to determine HER2 and TOP2A gene copy number by means of chromogenic in situ hybridization. Immunohistochemical staining of topoisomerase II alpha was also performed using a monoclonal antibody (Ki-S1). TOP2A amplification and protein expression were correlated with classical prognostic parameters, expression of immunohistochemical markers and with a gene expression profiling classification using surrogate immunohistochemical markers. Kaplan–Meier method was used to construct survival curves and results were compared with log-rank test. TOP2A amplification was restricted to tumours with HER2 amplification and was significantly associated with ER positivity. In the subgroup of patients with HER2 amplified tumours, TOP2A amplification predicted a better overall survival and disease free survival (P = 0.028 and 0.026, respectively). On multivariate analysis, TOP2A amplification maintained its predictive value for DFS. TOP2A amplification is likely to be a useful marker to predict the subset of patients who will benefit from anthracyclines.
         datePublished:2007-01-27T00:00:00Z
         dateModified:2007-01-27T00:00:00Z
         pageStart:181
         pageEnd:189
         sameAs:https://doi.org/10.1007/s10549-006-9492-5
         keywords:
            Anthracyclines
            Breast cancer
            Chromogenic in situ hubridisation
            HER2
            Topoisomerase II alpha
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-006-9492-5/MediaObjects/10549_2006_9492_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-006-9492-5/MediaObjects/10549_2006_9492_Fig2_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:106
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Edurne Arriola
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
                     name:Royal Marsden Hospital
                     address:
                        name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Socorro Maria Rodriguez-Pinilla
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maryou B. K. Lambros
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robin L. Jones
               affiliation:
                     name:Royal Marsden Hospital
                     address:
                        name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michelle James
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kay Savage
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ian E. Smith
               affiliation:
                     name:Royal Marsden Hospital
                     address:
                        name:Breast Unit, Royal Marsden Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mitch Dowsett
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
                     name:Royal Marsden Hospital
                     address:
                        name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jorge S. Reis-Filho
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
      description:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the impact of TOP2A amplification on the outcome of a series of patients homogeneously treated with adjuvant anthracyclines. A cohort of 245 patients with early breast cancer homogeneously treated with anthracyclines in the adjuvant setting was selected. A tissue microarray containing these cancers was used to determine HER2 and TOP2A gene copy number by means of chromogenic in situ hybridization. Immunohistochemical staining of topoisomerase II alpha was also performed using a monoclonal antibody (Ki-S1). TOP2A amplification and protein expression were correlated with classical prognostic parameters, expression of immunohistochemical markers and with a gene expression profiling classification using surrogate immunohistochemical markers. Kaplan–Meier method was used to construct survival curves and results were compared with log-rank test. TOP2A amplification was restricted to tumours with HER2 amplification and was significantly associated with ER positivity. In the subgroup of patients with HER2 amplified tumours, TOP2A amplification predicted a better overall survival and disease free survival (P = 0.028 and 0.026, respectively). On multivariate analysis, TOP2A amplification maintained its predictive value for DFS. TOP2A amplification is likely to be a useful marker to predict the subset of patients who will benefit from anthracyclines.
      datePublished:2007-01-27T00:00:00Z
      dateModified:2007-01-27T00:00:00Z
      pageStart:181
      pageEnd:189
      sameAs:https://doi.org/10.1007/s10549-006-9492-5
      keywords:
         Anthracyclines
         Breast cancer
         Chromogenic in situ hubridisation
         HER2
         Topoisomerase II alpha
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-006-9492-5/MediaObjects/10549_2006_9492_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-006-9492-5/MediaObjects/10549_2006_9492_Fig2_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:106
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Edurne Arriola
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
                  name:Royal Marsden Hospital
                  address:
                     name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Socorro Maria Rodriguez-Pinilla
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maryou B. K. Lambros
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robin L. Jones
            affiliation:
                  name:Royal Marsden Hospital
                  address:
                     name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michelle James
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kay Savage
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ian E. Smith
            affiliation:
                  name:Royal Marsden Hospital
                  address:
                     name:Breast Unit, Royal Marsden Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mitch Dowsett
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
                  name:Royal Marsden Hospital
                  address:
                     name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jorge S. Reis-Filho
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:106
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:Royal Marsden Hospital
      address:
         name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:Royal Marsden Hospital
      address:
         name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:Royal Marsden Hospital
      address:
         name:Breast Unit, Royal Marsden Hospital, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:Royal Marsden Hospital
      address:
         name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Edurne Arriola
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
            name:Royal Marsden Hospital
            address:
               name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:Socorro Maria Rodriguez-Pinilla
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      name:Maryou B. K. Lambros
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      name:Robin L. Jones
      affiliation:
            name:Royal Marsden Hospital
            address:
               name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:Michelle James
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      name:Kay Savage
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      name:Ian E. Smith
      affiliation:
            name:Royal Marsden Hospital
            address:
               name:Breast Unit, Royal Marsden Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:Mitch Dowsett
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
            name:Royal Marsden Hospital
            address:
               name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:Jorge S. Reis-Filho
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:Breast Unit, Royal Marsden Hospital, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(168)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.49s.

LINK . SPRINGER . COM {}